Who is sponsoring NCT05131776?

NCT05131776 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT05131776?

Interventions in NCT05131776: EUS-guided oncosil injection.

What condition does NCT05131776 study?

NCT05131776 studies Pancreatic Cancer, Endoscopic Ultrasound.

Is NCT05131776 still recruiting?

NCT05131776 is currently terminated. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT05131776

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.

Terminated Phase 2, PHASE3 Last updated 23 March 2026

What this trial tests

Phase 2, PHASE3 trial testing EUS-guided oncosil injection in Pancreatic Cancer in 2 participants. Terminated before completion.

Timeline

1 November 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	1 November 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

EUS-guided oncosil injection

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Endoscopic Ultrasound — all drugs for Endoscopic Ultrasound →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Pancreatic Cancer or Endoscopic Ultrasound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The outcomes of concurrent EUS-guided intra-tumour injection of P-32 microparticles (OncoSil; OncoSil Medical, Australia) with chemotherapy in locally advanced pancreatic carcinoma in the local population is uncertain. The aim of the current study is to assess efficacy and safety of the intervention in the local population. We hypothesis that the intervention is safe and useful for tumour downstaging.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
Zhang CY, Liu S, Yang M. · · 2022 · cited 28× · PMID 36632312 · DOI 10.3748/wjg.v28.i48.6827

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05131776 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05131776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing